-

Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column technology. Agilent has a 50-year history of innovation in gas chromatography, continually setting the standard for GC column performance. The new Agilent J&W 5Q GC/MS columns combine Agilent’s industry-recognized ultra-inert performance and ultra-low-bleed technology, delivering unmatched performance and durability for the most demanding applications.

In modern gas chromatography/mass spectrometry (GC/MS) workflows, GC/MS columns are often subjected to complex matrices and chemically active analytes that require reporting at trace levels. Under these conditions, maintaining the data quality needed to meet regulatory targets or other analytical requirements necessitates more frequent column changes, source cleaning, and potential sample re-runs, which decreases laboratory efficiency and increases costs.

Agilent J&W GC/MS 5Q columns provide exceptional peak symmetry for active analytes and set a new industry standard for minimal column bleed, enabling high sensitivity, maintaining accuracy and mass spectral fidelity, and accurate quantitation for the most challenging trace-level analytes. Additionally, these new GC/MS columns feature faster conditioning and are especially resistant to conditions that can shorten column life. Agilent J&W GC/MS 5Q columns enhance system performance in particularly difficult conditions, such as the use of hydrogen as a carrier gas, and in environmental workflows targeting emerging analytes of interest, where exceptional sensitivity and column durability are critical.

“This launch marks one of our most significant advancements in GC/MS column technology. The new J&W 5Q GC/MS columns are engineered to meet the rigorous demands of modern analytical laboratories,” said David Edwards, vice president and general manager of Agilent’s Chemistries Division. “By reducing the frequency of column changes and enhancing system performance, these columns not only improve data quality but also significantly boost laboratory efficiency and reduce operational costs.”

“Eagerly anticipated by our customers, this GC/MS column innovation underscores Agilent’s commitment to providing cutting-edge solutions that empower scientists to achieve their analytical goals with greater ease and reliability,” Edwards added.

Available in a range of dimensions, the Agilent J&W 5Q GC/MS columns extend the analytical options available to labs across a wide sector of markets and applications, including PFAS testing in environmental samples, analysis of residual pesticides in food, and more. Their enhanced performance strengthens Agilent’s position as a premium provider of solutions that push the boundaries of analytical methodology, allowing users of industry-leading Agilent GC/MS systems to extract even greater performance and value from their instruments.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides...

Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to...

Agilent Completes Acquisition of Biocare Medical

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st...
Back to Newsroom